


NOBORI 2 study


Two year clinical outcomes

Clinical outcomes




Nobori stent confirmed its safety and efficacy with a consistently low occurrence of clinical events throughout the trial.

TLF in patient/lesion subsets



In both challenging-lesion and high-risk patients subgroups, Nobori's TLF rate remained low.

Stent thrombosis



Nobori stent demonstrates a particularly low rate of late and very late stent thrombosis.


NOBORI 2 study

Two year clinical outcomes

Study design

3067 patients
125 centers (Europe, Asia, Australia)

Consecutive patients with coronary artery
disease eligible for treatment with DES



QCA lesion characteristics

	Simple n=825	Complex n=2242	Total Population	P-value
RVD, mm	2.61±0.57	2.61±0.58	2.61±0.58	0.89
Lesion Length, mm	15.27±9.25	15.68±9.68	15.59±9.59	0.52
MLD pre, mm	0.91±0.48	0.81±0.50	0.83±0.50	<0.001
MLD post, mm	2.52±0.46	2.50±0.47	2.51±0.47	0.23
DS – pre, %	65.4±16.2	68.9±17.8	68.2±17.5	<0.001
DS – post, %	12.6±6.6	13.2±7.1	13.1±7.0	0.19
Acute gain, mm	1.62±0.54	1.69±0.59	1.68±0.58	0.003